Literature DB >> 7275181

Production of an anti-tumour cytotoxin by human monocytes.

N Matthews.   

Abstract

Human monocytes incubated in vitro for 20 hr at 37 degrees release a factor which is cytotoxic to a number of human and murine tumour cell lines: untransformed cells appear to be less susceptible. A similar factor is produced under comparable conditions by myelomonocytic leukaemic cells and by macrophages derived from monocytes by in vitro culture for 8 days. Maximum production of the factor occurred in the presence of foetal calf serum or autologous plasma and endotoxin. The factor is newly synthesized in culture as its production is reduced if the monocytes are treated with cycloheximide or actinomycin D or incubated at lower temperatures. Freshly isolated monocytes do not release the factor on freeze--thaw or hypotonic lysis. The monocyte cytotoxin has apparent molecular weights of 34,000 on Ultrogel AcA54 gel filtration and 140,000 on gradient polyacrylamide gel electrophoresis; it has beta 2--gamma 1 electrophoretic mobility in polyacrylamide gel and does not appear to be C3a or arginase.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7275181      PMCID: PMC1555127     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  15 in total

1.  "Spontaneous" cytolysis by normal human lymphocytes of Burkitt's lymphoma cells of the EB2 cell line.

Authors:  N Matthews; B P Maclaurin
Journal:  Aust J Exp Biol Med Sci       Date:  1974-08

2.  Thymus-dependent and thymus-independent effector functions of mouse lymphoid cells. Comparison of cytotoxicity and primary antibody formation in vitro.

Authors:  S Britton; H Perlmann; P Perlmann
Journal:  Cell Immunol       Date:  1973-09       Impact factor: 4.868

3.  Selective cytotoxicity of peritoneal leucocytes for neoplastic cells.

Authors:  O A Holtermann; E Klein; G P Casale
Journal:  Cell Immunol       Date:  1973-12       Impact factor: 4.868

4.  Discrimination between neoplastic and non-neoplastic cells in vitro by activated macrophages.

Authors:  J B Hibbs
Journal:  J Natl Cancer Inst       Date:  1974-11       Impact factor: 13.506

5.  Cytotoxic activity of lymphocytes. V. Role of soluble toxin in macrophage-inhibited cultures of tumor cells.

Authors:  W P Reed; Z J Lucas
Journal:  J Immunol       Date:  1975-08       Impact factor: 5.422

6.  An endotoxin-induced serum factor that causes necrosis of tumors.

Authors:  E A Carswell; L J Old; R L Kassel; S Green; N Fiore; B Williamson
Journal:  Proc Natl Acad Sci U S A       Date:  1975-09       Impact factor: 11.205

7.  Activated macrophages kill tumour cells by releasing arginase.

Authors:  G A Currie
Journal:  Nature       Date:  1978-06-29       Impact factor: 49.962

8.  Production of the complement cleavage product, C3a, by activated macrophages and its tumorolytic effects.

Authors:  J Ferluga; H U Schorlemmer; L C Baptista; A C Allison
Journal:  Clin Exp Immunol       Date:  1978-03       Impact factor: 4.330

9.  Tumour-necrosis factor from the rabbit. I. Mode of action, specificity and physicochemical properties.

Authors:  N Matthews; J F Watkins
Journal:  Br J Cancer       Date:  1978-08       Impact factor: 7.640

10.  Tumour-necrosis factor from the rabbit. II. Production by monocytes.

Authors:  N Matthews
Journal:  Br J Cancer       Date:  1978-08       Impact factor: 7.640

View more
  30 in total

Review 1.  Long-Term Relationships: the Complicated Interplay between the Host and the Developmental Stages of Toxoplasma gondii during Acute and Chronic Infections.

Authors:  Kelly J Pittman; Laura J Knoll
Journal:  Microbiol Mol Biol Rev       Date:  2015-12       Impact factor: 11.056

2.  The role of monocyte cytotoxic factor in monocyte-mediated lysis of tumour cells.

Authors:  T Espevik; O Kildahl-Andersen; J Nissen-Meyer
Journal:  Immunology       Date:  1986-02       Impact factor: 7.397

3.  Potentiation of direct antitumor cytotoxicity and production of tumor cytolytic factors in human blood monocytes by human recombinant interferon-gamma and muramyl dipeptide derivatives.

Authors:  S Sone; G Lopez-Berestein; I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

4.  WEHI 164 sarcoma cells rendered resistant to monocyte-released cytotoxin are also resistant to monocyte-induced cytolysis.

Authors:  O Kildahl-Andersen; R Austgulen; J Nissen-Meyer
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

5.  Effect of lipopolysaccharides, lipid A and interferon on the cell-mediated cytotoxicity of human leukocytes against K-562 tumor cells.

Authors:  P C Fink; C Klaproth; H H Peter
Journal:  Infection       Date:  1984 Sep-Oct       Impact factor: 3.553

6.  Immune mechanisms and molecular mediators of glomerular injury in experimental nephritis. Summary of current results and continuing studies.

Authors:  Z Hruby; R P Lowry; R D Forbes; D Marghesco
Journal:  Int Urol Nephrol       Date:  1988       Impact factor: 2.370

7.  Cloning and expression in Escherichia coli of the cDNA for murine tumor necrosis factor.

Authors:  D Pennica; J S Hayflick; T S Bringman; M A Palladino; D V Goeddel
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

8.  Malarial parasites and tumour cells are killed by the same component of tumour necrosis serum.

Authors:  J Taverne; N Matthews; P Depledge; J H Playfair
Journal:  Clin Exp Immunol       Date:  1984-08       Impact factor: 4.330

9.  Effect of lipoarabinomannan and mycobacteria on tumour necrosis factor production by different populations of murine macrophages.

Authors:  M G Bradbury; C Moreno
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

10.  Increased production of tumor necrosis factor and prostaglandin E2 by monocytes in cancer patients and its unique modulation by their plasma.

Authors:  K Nara; H Odagiri; M Fujii; Y Yamanaka; M Yokoyama; T Morita; M Sasaki; M Kon; T Abo
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.